This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Janmaat, M. L. Articles by Giaccone, G. Search for Related Content PubMed PubMed Citation Articles by Janmaat, M. L. Articles by Giaccone, G.

Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells

Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways

VU University Medical Center, MB 1007 Amsterdam, the Netherlands

The epidermal growth factor receptor (EGFR) is an important novel target for anticancer therapy. In this study, we examined the molecular mechanisms that underlie the antitumor effects of the anti-EGFR monoclonal antibody C225 (Cetuximab) and the selective EGFR tyrosine kinase inhibitor ZD1839 (Iressa; AstraZeneca) in non-small cell lung cancer (NSCLC) cell lines. Cell growth, assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, was inhibited at low concentrations of ZD1839 and C225 in control A431 cells, whereas the NSCLC cell lines were comparatively more resistant. In A431 cells, but not in the NSCLC cells, ZD1839 treatment resulted in a modest increase in DNA fragmentation, the externalization of phosphatidyl serine, and the activation of caspase-3, known markers of apoptotic cell death. However, poly(ADP-ribose) polymerase cleavage was not detected, and caspase inhibition by carbobenzoxy-Val-Ala-Asp-fluoromethyl ketone partially reduced ZD1839-generated DNA fragmentation. Overexpression of the antiapoptotic protein Bcl-2 in A431 cells suppressed the cytotoxicity upon anti-EGFR treatment. These results thus demonstrate that the toxic effect of ZD1839 in A431 cells is caused by a form of cell death that involves a mitochondrial step and is, at least in part, dependent on caspase activation. EGFR expression levels showed no significant correlation with sensitivity to ZD1839 and C225. Evaluation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase and phosphatidylinositol 3'-kinase/Akt pathways showed considerable inhibition of these pathways by ZD1839 and C225 in A431 cells, whereas one or both of these pathways remained active upon anti-EGFR treatment in NSCLC cells. In addition, treatment with specific inhibitors of mitogen-activated protein kinase kinase or phosphatidylinositol 3'-kinase resulted in a smaller effect on proliferation than simultaneous treatment with both inhibitors, whereas induction of apoptosis was observed only when both pathways were blocked. Together, these data suggest that persistent activity of either of these signaling pathways is involved in the lack of sensitivity of NSCLC cell lines to EGFR inhibitors.

This article has been cited by other articles:

				S. Benavente, S. Huang, E. A. Armstrong, A. Chi, K.-T. Hsu, D. L. Wheeler, and P. M. Harari Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells Clin. Cancer Res., March 1, 2009; 15(5): 1585 - 1592. [Abstract] [Full Text] [PDF]

				D. Meco, T. Servidei, A. Riccardi, C. Ferlini, G. Cusano, G. F. Zannoni, F. Giangaspero, and R. Riccardi Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo Neuro-oncol, January 1, 2009; 11(3): 250 - 259. [Abstract] [Full Text] [PDF]

				I. Fichtner, J. Rolff, R. Soong, J. Hoffmann, S. Hammer, A. Sommer, M. Becker, and J. Merk Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers Clin. Cancer Res., October 15, 2008; 14(20): 6456 - 6468. [Abstract] [Full Text] [PDF]

				P. A. Zucali, M. G. Ruiz, E. Giovannetti, A. Destro, M. Varella-Garcia, K. Floor, G. L. Ceresoli, J. A. Rodriguez, I. Garassino, P. Comoglio, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors Ann. Onc., September 1, 2008; 19(9): 1605 - 1612. [Abstract] [Full Text] [PDF]

				M. S. Pino, M. Balsamo, F. Di Modugno, M. Mottolese, M. Alessio, E. Melucci, M. Milella, D. J. McConkey, U. Philippar, F. B. Gertler, et al. Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines Clin. Cancer Res., August 1, 2008; 14(15): 4943 - 4950. [Abstract] [Full Text] [PDF]

				I. N. Fleming, M. Hogben, S. Frame, S. J. McClue, and S. R. Green Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents Clin. Cancer Res., July 1, 2008; 14(13): 4326 - 4335. [Abstract] [Full Text] [PDF]

				A. Soeda, A. Inagaki, N. Oka, Y. Ikegame, H. Aoki, S.-i. Yoshimura, S. Nakashima, T. Kunisada, and T. Iwama Epidermal Growth Factor Plays a Crucial Role in Mitogenic Regulation of Human Brain Tumor Stem Cells J. Biol. Chem., April 18, 2008; 283(16): 10958 - 10966. [Abstract] [Full Text] [PDF]

				Y.-C. Wang, S. K. Kulp, D. Wang, C.-C. Yang, A. M. Sargeant, J.-H. Hung, Y. Kashida, M. Yamaguchi, G.-D. Chang, and C.-S. Chen Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors Cancer Res., April 15, 2008; 68(8): 2820 - 2830. [Abstract] [Full Text] [PDF]

				E. Giovannetti, C. Lemos, C. Tekle, K. Smid, S. Nannizzi, J. A. Rodriguez, S. Ricciardi, R. Danesi, G. Giaccone, and G. J. Peters Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells Mol. Pharmacol., April 1, 2008; 73(4): 1290 - 1300. [Abstract] [Full Text] [PDF]

				V. Benedetti, P. Perego, G. Luca Beretta, E. Corna, S. Tinelli, S. C. Righetti, R. Leone, P. Apostoli, C. Lanzi, and F. Zunino Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds Mol. Cancer Ther., March 1, 2008; 7(3): 679 - 687. [Abstract] [Full Text] [PDF]

				A. S. Tsao, D. He, B. Saigal, S. Liu, J. J. Lee, S. Bakkannagari, N. G. Ordonez, W. K. Hong, I. Wistuba, and F. M. Johnson Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion Mol. Cancer Ther., July 1, 2007; 6(7): 1962 - 1972. [Abstract] [Full Text] [PDF]

				B. C. Cho, C.-K. Im, M.-S. Park, S. K. Kim, J. Chang, J. P. Park, H. J. Choi, Y. J. Kim, S.-J. Shin, J. H. Sohn, et al. Phase II Study of Erlotinib in Advanced Non-Small-Cell Lung Cancer After Failure of Gefitinib J. Clin. Oncol., June 20, 2007; 25(18): 2528 - 2533. [Abstract] [Full Text] [PDF]

				F. Yamasaki, M. J. Johansen, D. Zhang, S. Krishnamurthy, E. Felix, C. Bartholomeusz, R. J. Aguilar, K. Kurisu, G. B. Mills, G. N. Hortobagyi, et al. Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt Cancer Res., June 15, 2007; 67(12): 5779 - 5788. [Abstract] [Full Text] [PDF]

				L. L. Garland, C. Rankin, D. R. Gandara, S. E. Rivkin, K. M. Scott, R. B. Nagle, A. J.P. Klein-Szanto, J. R. Testa, D. A. Altomare, and E. C. Borden Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study J. Clin. Oncol., June 10, 2007; 25(17): 2406 - 2413. [Abstract] [Full Text] [PDF]

				M. Koyama, Y. Matsuzaki, S. Yogosawa, T. Hitomi, M. Kawanaka, and T. Sakai ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway Mol. Cancer Ther., May 1, 2007; 6(5): 1579 - 1587. [Abstract] [Full Text] [PDF]

				T. G. Johns, R. M. Perera, S. C. Vernes, A. A. Vitali, D. X. Cao, W. K. Cavenee, A. M. Scott, and F. B. Furnari The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization Clin. Cancer Res., March 15, 2007; 13(6): 1911 - 1925. [Abstract] [Full Text] [PDF]

				A. Jimeno, B. Rubio-Viqueira, M. L. Amador, V. Grunwald, A. Maitra, C. Iacobuzio-Donahue, and M. Hidalgo Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer Mol. Cancer Ther., March 1, 2007; 6(3): 1079 - 1088. [Abstract] [Full Text] [PDF]

				T. Okano, T. Kondo, K. Fujii, T. Nishimura, T. Takano, Y. Ohe, K. Tsuta, Y. Matsuno, A. Gemma, H. Kato, et al. Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma Clin. Cancer Res., February 1, 2007; 13(3): 799 - 805. [Abstract] [Full Text] [PDF]

				I. R Hutcheson, J. M Knowlden, H. E Jones, R. S Burmi, R. A McClelland, D. Barrow, J. M W Gee, and R. I Nicholson Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S89 - S97. [Abstract] [Full Text] [PDF]

				H. Su, C. Bodenstein, R. A. Dumont, Y. Seimbille, S. Dubinett, M. E. Phelps, H. Herschman, J. Czernin, and W. Weber Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors. Clin. Cancer Res., October 1, 2006; 12(19): 5659 - 5667. [Abstract] [Full Text] [PDF]

				M. P. Cunningham, H. Thomas, Z. Fan, and H. Modjtahedi Responses of Human Colorectal Tumor Cells to Treatment with the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ICR62 Used Alone and in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib. Cancer Res., August 1, 2006; 66(15): 7708 - 7715. [Abstract] [Full Text] [PDF]

				J. A. Engelman and L. C. Cantley The Role of the ErbB Family Members in Non-Small Cell "Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors". Clin. Cancer Res., July 15, 2006; 12(14): 4372s - 4376s. [Abstract] [Full Text] [PDF]

				F. Cappuzzo, L. Toschi, G. Tallini, G. L. Ceresoli, I. Domenichini, S. Bartolini, G. Finocchiaro, E. Magrini, G. Metro, A. Cancellieri, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib Ann. Onc., July 1, 2006; 17(7): 1120 - 1127. [Abstract] [Full Text] [PDF]

				S.-W. Han, T.-Y. Kim, Y. K. Jeon, P. G. Hwang, S.-A. Im, K.-H. Lee, J. H. Kim, D.-W. Kim, D. S. Heo, N. K. Kim, et al. Optimization of Patient Selection for Gefitinib in Non-Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation Clin. Cancer Res., April 15, 2006; 12(8): 2538 - 2544. [Abstract] [Full Text] [PDF]

				M. L. Janmaat, M. I. Gallegos-Ruiz, J. A. Rodriguez, G. A. Meijer, W. L. Vervenne, D. J. Richel, C. Van Groeningen, and G. Giaccone Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients J. Clin. Oncol., April 1, 2006; 24(10): 1612 - 1619. [Abstract] [Full Text] [PDF]

				M. S. Pino, M. Shrader, C. H. Baker, F. Cognetti, H. Q. Xiong, J. L. Abbruzzese, and D. J. McConkey Transforming Growth Factor {alpha} Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines. Cancer Res., April 1, 2006; 66(7): 3802 - 3812. [Abstract] [Full Text] [PDF]

				F. Robert, G. Blumenschein, R. S. Herbst, F. V. Fossella, J. Tseng, M. N. Saleh, and M. Needle Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naive Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., December 20, 2005; 23(36): 9089 - 9096. [Abstract] [Full Text] [PDF]

				R. L. Yauch, T. Januario, D. A. Eberhard, G. Cavet, W. Zhu, L. Fu, T. Q. Pham, R. Soriano, J. Stinson, S. Seshagiri, et al. Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients Clin. Cancer Res., December 15, 2005; 11(24): 8686 - 8698. [Abstract] [Full Text] [PDF]

				C Festuccia, P Muzi, D Millimaggi, L Biordi, G L Gravina, S Speca, A Angelucci, V Dolo, C Vicentini, and M Bologna Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines Endocr. Relat. Cancer, December 1, 2005; 12(4): 983 - 998. [Abstract] [Full Text] [PDF]

				A. B. Lassman, M. R. Rossi, J. R. Razier, L. E. Abrey, F. S. Lieberman, C. N. Grefe, K. Lamborn, W. Pao, A. H. Shih, J. G. Kuhn, et al. Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 Clin. Cancer Res., November 1, 2005; 11(21): 7841 - 7850. [Abstract] [Full Text] [PDF]

				G. M. Springett, L. Bonham, A. Hummer, I. Linkov, D. Misra, C. Ma, G. Pezzoni, S. Di Giovine, J. Singer, H. Kawasaki, et al. Lysophosphatidic Acid Acyltransferase-{beta} Is a Prognostic Marker and Therapeutic Target in Gynecologic Malignancies Cancer Res., October 15, 2005; 65(20): 9415 - 9425. [Abstract] [Full Text] [PDF]

				E. Lesma, V. Grande, S. Carelli, D. Brancaccio, M. P. Canevini, R. M. Alfano, G. Coggi, A. M. Di Giulio, and A. Gorio Isolation and Growth of Smooth Muscle-Like Cells Derived from Tuberous Sclerosis Complex-2 Human Renal Angiomyolipoma: Epidermal Growth Factor Is the Required Growth Factor Am. J. Pathol., October 1, 2005; 167(4): 1093 - 1103. [Abstract] [Full Text] [PDF]

				F. M. Johnson, B. Saigal, M. Talpaz, and N. J. Donato Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non-Small Cell Lung Cancer Cells Clin. Cancer Res., October 1, 2005; 11(19): 6924 - 6932. [Abstract] [Full Text] [PDF]

				T. Mukohara, J. A. Engelman, N. H. Hanna, B. Y. Yeap, S. Kobayashi, N. Lindeman, B. Halmos, J. Pearlberg, Z. Tsuchihashi, L. C. Cantley, et al. Differential Effects of Gefitinib and Cetuximab on Non-small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations J Natl Cancer Inst, August 17, 2005; 97(16): 1185 - 1194. [Abstract] [Full Text] [PDF]

				A. Jain, C. A. Tindell, I. Laux, J. B. Hunter, J. Curran, A. Galkin, D. E. Afar, N. Aronson, S. Shak, R. B. Natale, et al. Epithelial membrane protein-1 is a biomarker of gefitinib resistance PNAS, August 16, 2005; 102(33): 11858 - 11863. [Abstract] [Full Text] [PDF]

				M. L. Janmaat, J. A. Rodriguez, J. Jimeno, F. A. E. Kruyt, and G. Giaccone Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling Mol. Pharmacol., August 1, 2005; 68(2): 502 - 510. [Abstract] [Full Text] [PDF]

				Z. Zheng, G. Bepler, A. Cantor, and E. B. Haura Small Tumor Size and Limited Smoking History Predicts Activated Epidermal Growth Factor Receptor in Early-Stage Non-small Cell Lung Cancer Chest, July 1, 2005; 128(1): 308 - 316. [Abstract] [Full Text] [PDF]

				D. A. Haas-Kogan, M. D. Prados, T. Tihan, D. A. Eberhard, N. Jelluma, N. D. Arvold, R. Baumber, K. R. Lamborn, A. Kapadia, M. Malec, et al. Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib J Natl Cancer Inst, June 15, 2005; 97(12): 880 - 887. [Abstract] [Full Text] [PDF]

				X. L. Mu, L. Y. Li, X. T. Zhang, M. Z. Wang, R. E. Feng, Q. C. Cui, H. S. Zhou, and B. Q. Guo Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., June 15, 2005; 11(12): 4289 - 4294. [Abstract] [Full Text] [PDF]

				N. Normanno and A. De Luca In Reply: J. Clin. Oncol., June 1, 2005; 23(16): 3866 - 3867. [Full Text] [PDF]

				A. Hirata, F. Hosoi, M. Miyagawa, S.-i. Ueda, S. Naito, T. Fujii, M. Kuwano, and M. Ono HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells Cancer Res., May 15, 2005; 65(10): 4253 - 4260. [Abstract] [Full Text] [PDF]

				F. Cappuzzo, F. R. Hirsch, E. Rossi, S. Bartolini, G. L. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini, et al. Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer J Natl Cancer Inst, May 4, 2005; 97(9): 643 - 655. [Abstract] [Full Text] [PDF]

				G. W. Cole Jr, A. M. Alleva, R. M. Reddy, J. B. Maxhimer, J. Zuo, D. S. Schrump, and D. M. Nguyen The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1010 - 1017. [Abstract] [Full Text] [PDF]

				N. Haruki, K. S. Kawaguchi, S. Eichenberger, P. P. Massion, S. Olson, A. Gonzalez, D. P. Carbone, and T. P. Dang Dominant-Negative Notch3 Receptor Inhibits Mitogen-Activated Protein Kinase Pathway and the Growth of Human Lung Cancers Cancer Res., May 1, 2005; 65(9): 3555 - 3561. [Abstract] [Full Text] [PDF]

				S.-W. Han, T.-Y. Kim, P. G. Hwang, S. Jeong, J. Kim, I. S. Choi, D.-Y. Oh, J. H. Kim, D.-W. Kim, D. H. Chung, et al. Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib J. Clin. Oncol., April 10, 2005; 23(11): 2493 - 2501. [Abstract] [Full Text] [PDF]

				K.-S. Kim, J.-Y. Jeong, Y.-C. Kim, K.-J. Na, Y.-H. Kim, S.-J. Ahn, S.-M. Baek, C.-S. Park, C.-M. Park, Y.-I. Kim, et al. Predictors of the Response to Gefitinib in Refractory Non-Small Cell Lung Cancer Clin. Cancer Res., March 15, 2005; 11(6): 2244 - 2251. [Abstract] [Full Text] [PDF]

				A. J. Mantha, J. E.L. Hanson, G. Goss, A. E. Lagarde, I. A. Lorimer, and J. Dimitroulakos Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor Clin. Cancer Res., March 15, 2005; 11(6): 2398 - 2407. [Abstract] [Full Text] [PDF]

				J. A. Engelman, P. A. Janne, C. Mermel, J. Pearlberg, T. Mukohara, C. Fleet, K. Cichowski, B. E. Johnson, and L. C. Cantley ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines PNAS, March 8, 2005; 102(10): 3788 - 3793. [Abstract] [Full Text] [PDF]

				A. Cesario, A. Catassi, L. Festi, A. Imperatori, A. Pericelli, D. Galetta, S. Margaritora, V. Porziella, V. Cardaci, P. Granone, et al. Farnesyltransferase Inhibitors and Human Malignant Pleural Mesothelioma: A First-Step Comparative Translational Study Clin. Cancer Res., March 1, 2005; 11(5): 2026 - 2037. [Abstract] [Full Text] [PDF]

				D. Raben, B. Helfrich, D. C. Chan, F. Ciardiello, L. Zhao, W. Franklin, A. E. Baron, C. Zeng, T. K. Johnson, and P. A. Bunn Jr The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer Clin. Cancer Res., January 15, 2005; 11(2): 795 - 805. [Abstract] [Full Text] [PDF]

				S. Skvortsov, B. Sarg, J. Loeffler-Ragg, I. Skvortsova, H. Lindner, H. Werner Ott, P. Lukas, K. Illmensee, and H. Zwierzina Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment Mol. Cancer Ther., December 1, 2004; 3(12): 1551 - 1558. [Abstract] [Full Text] [PDF]

				P. P. Massion, P. M. Taflan, Y. Shyr, S. M. J. Rahman, P. Yildiz, B. Shakthour, M. E. Edgerton, M. Ninan, J. J. Andersen, and A. L. Gonzalez Early Involvement of the Phosphatidylinositol 3-Kinase/Akt Pathway in Lung Cancer Progression Am. J. Respir. Crit. Care Med., November 15, 2004; 170(10): 1088 - 1094. [Abstract] [Full Text] [PDF]

				B. R. Balsara, J. Pei, Y. Mitsuuchi, R. Page, A. Klein-Szanto, H. Wang, M. Unger, and J. R. Testa Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions Carcinogenesis, November 1, 2004; 25(11): 2053 - 2059. [Abstract] [Full Text] [PDF]

				S. Tracy, T. Mukohara, M. Hansen, M. Meyerson, B. E. Johnson, and P. A. Janne Gefitinib Induces Apoptosis in the EGFRL858R Non-Small-Cell Lung Cancer Cell Line H3255 Cancer Res., October 15, 2004; 64(20): 7241 - 7244. [Abstract] [Full Text] [PDF]

				B. Friedmann, M. Caplin, J. A. Hartley, and D. Hochhauser Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839) Clin. Cancer Res., October 1, 2004; 10(19): 6476 - 6486. [Abstract] [Full Text] [PDF]

				F. Cappuzzo, E. Magrini, G. L. Ceresoli, S. Bartolini, E. Rossi, V. Ludovini, V. Gregorc, C. Ligorio, A. Cancellieri, S. Damiani, et al. Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, August 4, 2004; 96(15): 1133 - 1141. [Abstract] [Full Text] [PDF]

				S. Huang, E. A. Armstrong, S. Benavente, P. Chinnaiyan, and P. M. Harari Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR): Combining Anti-EGFR Antibody with Tyrosine Kinase Inhibitor Cancer Res., August 1, 2004; 64(15): 5355 - 5362. [Abstract] [Full Text] [PDF]

				G. V. Scagliotti, G. Selvaggi, S. Novello, and F. R. Hirsch The Biology of Epidermal Growth Factor Receptor in Lung Cancer Clin. Cancer Res., June 15, 2004; 10(12): 4227S - 4232S. [Abstract] [Full Text] [PDF]

				G. Giaccone The Role of Gefitinib in Lung Cancer Treatment Clin. Cancer Res., June 15, 2004; 10(12): 4233S - 4237S. [Abstract] [Full Text] [PDF]

				S. Vicent, M. Garayoa, J. M. Lopez-Picazo, M. D. Lozano, G. Toledo, F. B. J. M. Thunnissen, R. G. Manzano, and L. M. Montuenga Mitogen-Activated Protein Kinase Phosphatase-1 Is Overexpressed in Non-Small Cell Lung Cancer and Is an Independent Predictor of Outcome in Patients Clin. Cancer Res., June 1, 2004; 10(11): 3639 - 3649. [Abstract] [Full Text] [PDF]

				F. Cappuzzo In Reply: J. Clin. Oncol., May 15, 2004; 22(10): 2036 - 2037. [Full Text] [PDF]

				N. Normanno, M. Di Maio, F. Perrone, and M. Campiglio Molecular Markers to Predict Response to Gefitinib: EGFR, ErbB-2, or More? J. Clin. Oncol., May 15, 2004; 22(10): 2035 - 2036. [Full Text] [PDF]

				R. Perez-Soler HER1/EGFR Targeting: Refining the Strategy Oncologist, February 1, 2004; 9(1): 58 - 67. [Abstract] [Full Text] [PDF]

				M. L. Janmaat and G. Giaccone Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist, December 1, 2003; 8(6): 576 - 586. [Abstract] [Full Text] [PDF]